Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Budapest – page 7

1 052 clinical trials in Budapest, Hungary across 10 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Budapest at a glance
1 052
clinical trials
  • Research sites10
Type of trial
Recruitment status
Quick filters

1 052 trials in Budapest

Open in trial search

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Neoplasm malignant

Recruiting

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Atrial fibrillation

Recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:HungaryHungary
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Sjogren's syndrome

Recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Obstructive sleep apnoea syndrome

Recruiting

A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Dilated cardiomyopathy

Recruiting

Long‑Term Safety and Efficacy Study of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Kardigan Inc.

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Heart failure with reduced ejection fraction

Recruiting

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Small cell lung cancer extensive stage

Recruiting

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Type 2 diabetes mellitus

Recruiting

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Budapest

What the registry says about research in the country

01 Immunology & Inflammatory Conditions

Research focusing on innovative treatments for inflammatory disorders, including studies on new therapies for psoriasis, psoriatic arthritis, and chronic urticaria.

  • Plaque Psoriasis Treatment Evaluation
  • Psoriatic Arthritis Management
  • Chronic Urticaria Therapy

Multiple clinical trials are investigating targeted therapies and their long-term effectiveness in managing inflammatory conditions.

02 Infectious Diseases & Prevention

Studies centered on preventing and treating various infections, with particular emphasis on meningococcal vaccines and respiratory conditions.

  • Meningococcal Vaccine Studies
  • RSV Prevention in Children
  • Bacterial Infection Treatments

Research includes both preventive vaccines and therapeutic approaches for various infectious diseases.

03 Chronic Diseases & Cardiovascular Health

Comprehensive research into heart failure prevention and management of chronic conditions, including studies on kidney disease and obesity.

  • Heart Failure Prevention
  • Chronic Kidney Disease Management
  • Obesity Treatment Studies

Investigations focus on innovative therapeutic combinations and their impact on cardiovascular outcomes.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.